Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (101-110 of 687) with videos related to

Pageof 69
Sort By:
European Journal of Heart Failure|December 5, 2015
Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?Bertram Pitt, Matthew R Weir
Nature Clinical Practice. Cardiovascular Medicine|December 17, 2008
Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapiesRobert S Rosenson, Bertram Pitt
Circulation|June 15, 2007
Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac deathBertram Pitt, Geoffrey S Pitt
JACC. Cardiovascular Imaging|September 20, 2020
Primary Aldosteronism: New Insights Into its Detection and Cardiac InvolvementBertram Pitt, James Brian Byrd
Hypertension (Dallas, Tex. : 1979)|June 2, 2026
Management of Diuretic Induced Hypokalemia in Elderly HypertensivesBertram Pitt, Christopher S Wilcox
European Heart Journal|July 2, 2026
Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesisLars H Lund, Bertram Pitt
JACC. Heart Failure|December 14, 2020
ARNI and MRA Combination in PARAGON-HF: Odd Couple or Dynamic Duo?Ralph J Riello, Bertram Pitt
European Heart Journal|December 1, 2020
Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunitiesBertram Pitt, James Brian Byrd
European Heart Journal|May 24, 2023
Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockadeBertram Pitt, George L Bakris
Hypertension (Dallas, Tex. : 1979)|November 1, 2023
Chlorthalidone or Spironolactone for Patients With TRH and Advanced Chronic Kidney Disease?Bertram Pitt, Richard J Auchus
Pageof 69

Showing results (101-110 of 687) with videos related to

Sort By:
Pageof 69
European Journal of Heart Failure|December 5, 2015
Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?Bertram Pitt, Matthew R Weir
Nature Clinical Practice. Cardiovascular Medicine|December 17, 2008
Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapiesRobert S Rosenson, Bertram Pitt
Circulation|June 15, 2007
Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac deathBertram Pitt, Geoffrey S Pitt
JACC. Cardiovascular Imaging|September 20, 2020
Primary Aldosteronism: New Insights Into its Detection and Cardiac InvolvementBertram Pitt, James Brian Byrd
Hypertension (Dallas, Tex. : 1979)|June 2, 2026
Management of Diuretic Induced Hypokalemia in Elderly HypertensivesBertram Pitt, Christopher S Wilcox
European Heart Journal|July 2, 2026
Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesisLars H Lund, Bertram Pitt
JACC. Heart Failure|December 14, 2020
ARNI and MRA Combination in PARAGON-HF: Odd Couple or Dynamic Duo?Ralph J Riello, Bertram Pitt
European Heart Journal|December 1, 2020
Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunitiesBertram Pitt, James Brian Byrd
European Heart Journal|May 24, 2023
Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockadeBertram Pitt, George L Bakris
Hypertension (Dallas, Tex. : 1979)|November 1, 2023
Chlorthalidone or Spironolactone for Patients With TRH and Advanced Chronic Kidney Disease?Bertram Pitt, Richard J Auchus
Pageof 69